Undisclosed DIO3 inhibitor / Dio Tree - LARVOL DELTA

First-in-class DIO3 inhibitor as a novel treatment strategy in ovarian cancer. (ASCO 2026) - "Antitumor efficacy was tested in nude mice bearing homologous recombination-proficient (HRP), carboplatin-resistant ovarian cancer xenografts. These data support advancement of ITYR-DBRMD toward early-phase clinical testing, with potential application in ovarian cancer patients, a population lacking targeted therapeutic options."

Oncology • Ovarian Cancer • Solid Tumor